StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)

Fri, 04 Sep 2026 06:46:52 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $8.00 price target on Milestone Pharmaceuticals (NASDAQ: MIST).

The analyst commented: "MIST's partner announced NMPA approval of etripamil nasal spray for PSVT in adults in China, the first approval for etripamil outside the U.S., which we view as incrementally positive and supportive of our Buy thesis. The approval triggers a $2M milestone payment from partner Everest Medicines (HKG: 1952, not rated), which will lead commercialization in Greater China, while MIST remains eligible for up to an additional $98M in development and commercial milestones and tiered royalties of up to 18% on

Milestone study finds PSVT impacts patient life between episodes

Thu, 27 Aug 2026 08:01:06 -0400

Milestone Pharmaceuticals (Nasdaq: MIST) presented findings from a longitudinal study on paroxysmal supraventricular tachycardia (PSVT) at the European Society of Cardiology Congress 2026 on August 30, showing that the heart rhythm disorder burdens patients even between acute episodes.

The study, funded by Milestone Pharmaceuticals, enrolled 247 adults in the United States and United Kingdom with a self-reported PSVT diagnosis and no history of catheter ablation. Participants completed surveys from February 2019 through December 2019. The mean participant age was 52 years, and 72% were female.

Key findings include that approximately two in three patients adjusted their lifestyle between episodes to avoid stress,

Milestone study finds PSVT impacts patient life between episodes

Thu, 27 Aug 2026 08:01:06 -0400

Key findings include that approximately two in three patients adjusted their lifestyle between episodes to avoid stress,

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes” at the European Society of Cardiology (ESC) Congress 2026 on August 30, 2026, 15:15-16:00 CET, Station 6,

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Thu, 27 Aug 2026 08:00:00 -0400

Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil

Fri, 21 Aug 2026 08:00:28 -0400

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced Aug. 21, 2026, that the first patient has been enrolled in the ReVeRA-301 Phase 3 trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR).

The multinational, randomized, double-blind, placebo-controlled study targets approximately 150 patients. It uses the same 70 mg repeat-dose regimen as the pivotal trials for etripamil, which is FDA-approved under the brand name Cardamyst for paroxysmal supraventricular tachycardia (PSVT). The primary endpoint is reduction in ventricular rate within 30 minutes, with a key secondary endpoint of patient-reported symptom improvement.

Milestone said it is pursuing a single-study supplemental new drug application

Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil

Fri, 21 Aug 2026 08:00:28 -0400

Milestone said it is pursuing a single-study supplemental new drug application

Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil

Fri, 21 Aug 2026 08:00:28 -0400

Milestone said it is pursuing a single-study supplemental new drug application

Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil

Fri, 21 Aug 2026 08:00:28 -0400

Milestone said it is pursuing a single-study supplemental new drug application

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)